Canaloplasty Market Size and Share Analysis - Growth Trends and Forecasts (2026-2033)

Market Size and Trends

The Canaloplasty market is estimated to be valued at USD 1.2 billion in 2026 and is expected to reach USD 2.1 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.5% from 2026 to 2033. This robust growth reflects increasing adoption of minimally invasive glaucoma surgeries and rising prevalence of glaucoma worldwide, driving demand for advanced and effective treatment options such as canaloplasty.

Current market trends highlight a significant shift toward less invasive procedures with quicker recovery times, fueling canaloplasty's popularity among patients and healthcare providers. Innovations in surgical devices and growing awareness about glaucoma management are further propelling market expansion. Additionally, favorable reimbursement policies and increasing investments in ophthalmic technologies are expected to sustain the upward momentum over the forecast period.

Segmental Analysis:

By Procedure Type: Dominance of Ab-externo Canaloplasty Driven by Surgical Precision and Established Clinical Outcomes

In terms of By Procedure Type, Ab-externo Canaloplasty contributes the highest share of the market owing to its well-established clinical track record and the higher level of precision it offers during glaucoma surgery. This type of canaloplasty involves an external approach that enables surgeons to directly visualize Schlemm's canal and surrounding ocular tissues. Such visibility allows for more accurate and controlled dilation and tensioning of the canal, which is a critical factor in lowering intraocular pressure effectively. The technique's reliability and predictability have made it the preferred choice among ophthalmic surgeons, particularly for patients with open-angle glaucoma who require long-term pressure management without the need for bleb formation. Furthermore, Ab-externo canaloplasty requires specialized surgical skills but delivers superior outcomes that minimize postoperative complications. The incremental adoption of newer microsurgical instruments has also enhanced the efficacy and safety profile of this procedure, positively influencing patient satisfaction and surgeon preference. While newer procedures such as Ab-interno canaloplasty and combined procedures are gaining traction due to their minimally invasive nature, Ab-externo canaloplasty's extensive clinical validation and ability to treat a broader spectrum of disease severity sustain its market prominence. Hospitals and specialty clinics, where experienced surgeons and comprehensive postoperative care are available, tend to prefer this technique, reinforcing its market leadership.

By End User: Hospitals Lead Market Share on Account of Comprehensive Care and Advanced Infrastructure

In terms of By End User, hospitals contribute the highest share of the Canaloplasty market, driven largely by their ability to offer comprehensive ophthalmic care and advanced surgical infrastructure. Hospitals typically have access to cutting-edge technology, multidisciplinary teams, and post-surgical monitoring capabilities, making them the preferred destination for complex glaucoma interventions such as canaloplasty. The versatility offered by hospitals in managing preoperative diagnostics, surgical procedures, and postoperative follow-ups ensures optimal patient outcomes, which is particularly crucial for a surgery like canaloplasty that necessitates precise intraoperative handling and close postoperative monitoring. Additionally, hospitals are more likely to attract referrals for cases requiring skilled surgical expertise, including those patients who have not responded adequately to medical therapy or less invasive procedures. Their established reimbursement pathways and alignment with insurance providers further facilitate patient access to canaloplasty. The growing emphasis on raising awareness about glaucoma treatment options in hospital settings, alongside continuous educational initiatives for healthcare professionals, also strengthens hospital dominance. Ambulatory surgical centers and specialty clinics are emerging as key players owing to convenience and cost-effectiveness but remain secondary to hospitals due to limitations in infrastructure and patient volume for advanced glaucoma surgeries.

By Device Type: Microcatheters Gain Leading Edge Through Precision and Minimally Invasive Capability

By Device Type, microcatheters contribute the highest share of the Canaloplasty market as a result of their pivotal role in enabling precision and minimally invasive treatment of glaucoma. Microcatheters are essential for effectively cannulating Schlemm's canal, facilitating controlled viscodilation, and allowing surgeons to place tensioning sutures that restore natural aqueous humor outflow. Their small size and flexibility make them ideal for navigating delicate ocular anatomy with minimal trauma, which translates into reduced surgical complications and shorter recovery times. Innovations in microcatheter design, such as enhanced flexibility, increased visibility via integrated illumination, and improved maneuverability, have contributed significantly to their acceptance and preference among ophthalmic surgeons. Compared to other devices like stents and viscodilation instruments, microcatheters offer a unique combination of precision and ease of use, making them indispensable for both Ab-externo and Ab-interno canaloplasty procedures. Furthermore, their compatibility with a range of adjunctive devices and procedural techniques enables tailored and patient-specific treatment approaches. The continuous development of microcatheter technology aligns closely with the broader trends in minimally invasive glaucoma surgeries (MIGS), reinforcing their market leadership. Other devices classified under viscodilation, stents, and miscellaneous tools, although important, have yet to surpass microcatheters in terms of utility and surgeon preference for canaloplasty interventions.

Regional Insights:

Dominating Region: North America

In North America, the dominance in the canaloplasty market is primarily driven by the well-established healthcare infrastructure and high adoption of advanced ophthalmic technologies. The robust presence of prominent medical device manufacturers such as Glaukos Corporation and Ivantis, which have pioneered innovations in minimally invasive glaucoma surgeries, significantly contributes to this region's lead. Additionally, supportive government policies, including FDA approvals and favorable reimbursement frameworks, bolster market growth. The availability of skilled ophthalmologists and an increasing prevalence of glaucoma further sustain strong demand. Moreover, collaborations between healthcare providers and research institutions foster product development and clinical adoption, reinforcing North America's commanding position in the canaloplasty market ecosystem.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific exhibits the fastest growth in the canaloplasty market, energized by expanding healthcare access, rising awareness of glaucoma, and increasing investments in ophthalmic care within emerging economies such as China and India. Government initiatives aiming to improve eye care infrastructure and streamline regulatory processes have facilitated faster market entry for new canaloplasty devices. The growing middle class and increased private healthcare expenditure are boosting demand for minimally invasive glaucoma surgeries. Industry players like Santen Pharmaceutical and HOYA Corporation actively engage in this region by establishing localized manufacturing units and conducting region-specific clinical trials. Additionally, international partnerships and technology transfer agreements accelerate adoption, positioning Asia Pacific as the fastest-growing market for canaloplasty.

Canaloplasty Market Outlook for Key Countries

United States

The United States market continues to lead canaloplasty with widespread adoption driven by early technology acceptance and strong private healthcare spending. Major players such as Glaukos Corporation have introduced innovative devices that have gained FDA clearance, making the procedure more accessible. The country benefits from extensive clinical research and training programs that increase surgeon expertise and patient awareness, ensuring sustained demand for canaloplasty treatments.

Germany

Germany's canaloplasty market benefits from advanced healthcare infrastructure and a well-established medical device industry. The country observes steady demand fostered by supportive reimbursement policies and the presence of firms like Carl Zeiss Meditec, which offer cutting-edge glaucoma treatment solutions. Germany's focus on precision medical technology and strong regulatory support for innovation further stimulates adoption of canaloplasty procedures.

China

China is emerging as a key growth driver for the canaloplasty market in Asia Pacific, propelled by government initiatives aimed at expanding access to advanced ophthalmic care. Increasing prevalence of glaucoma, combined with rising healthcare spending, has attracted multinational companies like Santen Pharmaceutical to localize manufacturing and expand distribution networks. Collaborative efforts between local healthcare providers and global players are accelerating awareness and adoption of minimally invasive glaucoma surgeries including canaloplasty.

Japan

Japan continues to lead in Asia Pacific's mature ophthalmology segment with a preference toward minimally invasive devices. Companies such as HOYA Corporation contribute to the market through continuous innovation and a strong domestic distribution network. Japan's aging population and increasing investments in eye care technology support the adoption of sophisticated canaloplasty systems, complemented by regulatory efficiency and established reimbursement schemes.

Brazil

Brazil's canaloplasty market reflects the broader expansion of healthcare infrastructure in Latin America, supported by rising awareness and government health programs targeting chronic eye diseases. Local medical device companies, along with international firms entering the market, are facilitating wider accessibility to canaloplasty procedures. Despite challenges in reimbursement and uneven healthcare distribution, Brazil offers significant growth potential driven by improving clinical capabilities and growing patient demand.

Market Report Scope

Market Segmentation

Procedure Type Insights (Revenue, USD, 2021 - 2033)

• Ab-externo Canaloplasty
• Ab-interno Canaloplasty
• Combined Procedures
• Others

End User Insights (Revenue, USD, 2021 - 2033)

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Device Type Insights (Revenue, USD, 2021 - 2033)

• Microcatheters
• Viscodilation Devices
• Stents
• Others

Regional Insights (Revenue, USD, 2021 - 2033)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Alcon Laboratories
• Allergan, Inc.
• Glaukos Corporation
• Ivantis, Inc.
• Santen Pharmaceutical Co., Ltd.
• Bausch Health Companies Inc.
• iScience Interventional
• MicroSurgical Technology, Inc.
• NeoMedix Corporation
• Carl Zeiss Meditec AG
• Abbott Laboratories
• Ellex Medical Lasers Limited
• Ivoy Medical